WO2001034633A3 - Methods for treatment of human huntington's disease and methods of screening for active agents - Google Patents

Methods for treatment of human huntington's disease and methods of screening for active agents Download PDF

Info

Publication number
WO2001034633A3
WO2001034633A3 PCT/US2000/030900 US0030900W WO0134633A3 WO 2001034633 A3 WO2001034633 A3 WO 2001034633A3 US 0030900 W US0030900 W US 0030900W WO 0134633 A3 WO0134633 A3 WO 0134633A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
methods
huntington
determined
screening
Prior art date
Application number
PCT/US2000/030900
Other languages
French (fr)
Other versions
WO2001034633A2 (en
Inventor
James M Olson
Ruth Luthi-Carter
Anne Young
Andrew Strand
Original Assignee
Hutchinson Fred Cancer Res
Gen Hospital Corp
James M Olson
Luthi Carter Ruth
Anne Young
Andrew Strand
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer Res, Gen Hospital Corp, James M Olson, Luthi Carter Ruth, Anne Young, Andrew Strand filed Critical Hutchinson Fred Cancer Res
Priority to AU17602/01A priority Critical patent/AU1760201A/en
Publication of WO2001034633A2 publication Critical patent/WO2001034633A2/en
Publication of WO2001034633A3 publication Critical patent/WO2001034633A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Genes modulated by the expression of a mutant huntingtin protein associated with Huntington's Disease have been determined. A profile of mRNAs that are modulated has been established as neurodegeneration progresses through the disease. Levels of mRNA encoding components of neurotransmitters, calcium and retinoid signaling pathways at both early and late symptomatic disease states have been established. Methods for the treatment or amelioration of disease have been determined based on the mRNA profile determined. Further, methods for screening for agents active in ameliorating and/or preventing progression of Huntington's Disease can be determined by examining changes in the level of expression of the mRNAs and/or proteins of the Huntington's Disease profile of the present invention.
PCT/US2000/030900 1999-11-12 2000-11-10 Methods for treatment of human huntington's disease and methods of screening for active agents WO2001034633A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU17602/01A AU1760201A (en) 1999-11-12 2000-11-10 Methods for treatment of human huntington's disease and methods of screening foractive agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16507999P 1999-11-12 1999-11-12
US60/165,079 1999-11-12

Publications (2)

Publication Number Publication Date
WO2001034633A2 WO2001034633A2 (en) 2001-05-17
WO2001034633A3 true WO2001034633A3 (en) 2002-01-10

Family

ID=22597330

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030900 WO2001034633A2 (en) 1999-11-12 2000-11-10 Methods for treatment of human huntington's disease and methods of screening for active agents

Country Status (2)

Country Link
AU (1) AU1760201A (en)
WO (1) WO2001034633A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002337442A1 (en) * 2001-09-24 2003-04-07 University Of Aarhus Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia
US20080027031A1 (en) * 2006-03-08 2008-01-31 Kinemed, Inc. Retinoids and Related Compounds for the Treatment of Neuroinflammatory Conditions, Diseases and Disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037648A1 (en) * 1996-04-05 1997-10-16 C.I.R.D. Galderma Use of benzonaphthalene derivatives to make medicaments for treating diseases of the central nervous system
WO1999006060A1 (en) * 1997-08-04 1999-02-11 The Regents Of The University Of California Methods for treating neurological deficits
US5880153A (en) * 1995-11-13 1999-03-09 Spinal Cord Society Method for upregulation of TRKB and TRKC receptors in central nervous system neurons

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880153A (en) * 1995-11-13 1999-03-09 Spinal Cord Society Method for upregulation of TRKB and TRKC receptors in central nervous system neurons
WO1997037648A1 (en) * 1996-04-05 1997-10-16 C.I.R.D. Galderma Use of benzonaphthalene derivatives to make medicaments for treating diseases of the central nervous system
WO1999006060A1 (en) * 1997-08-04 1999-02-11 The Regents Of The University Of California Methods for treating neurological deficits

Also Published As

Publication number Publication date
AU1760201A (en) 2001-06-06
WO2001034633A2 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
IL137858A0 (en) Modified ciliary neurotrophic factor, method of making and methods of use thereof
WO2002040544A3 (en) Mutant human factor ix with an increased resistance to inhibition by heparin
CA2274596A1 (en) Compositions and methods for enhancing intestinal function
WO2001084149A3 (en) Diagnostics and therapeutics for macular degeneration-related disorders
WO1999048482A3 (en) Smilagenin and anzurogenin-d for the treatment of alzheimer's disease
WO2001070977A3 (en) Fibroblast growth factor receptor-like molecules and uses thereof
WO2000018954A3 (en) Use of pex in the treatment of metabolic bone diseases
HK1043019A1 (en) Compositions and methods for prevention and treatment of protozoal disease.
WO2004058185A3 (en) Antiangiogenesis by inhibiting protein kinase ck2 activity
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2003031650A3 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
WO1998020880A3 (en) 11-Halo prostaglandins for the treatment of glaucoma or ocular hypertension
WO2001068854A3 (en) Fibroblast growth factor-like molecules and uses thereof
WO2000052479A3 (en) Diagnostics and therapeutics for drusen associated ocular disorders
WO1999066072A3 (en) Methods for treating a neurological disease by determining bche genotype
WO2001016377A3 (en) Diagnostics and therapeutics for osteoporosis
WO2002022871A3 (en) Polymorphic bone morphogenetic protein 2
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
WO2002059346A3 (en) Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents
CA2347863A1 (en) Treatment of disorders of the outer retina
WO1999054460A3 (en) Human nucleic acid sequences of normal bladder tissue
WO2001034633A3 (en) Methods for treatment of human huntington's disease and methods of screening for active agents
MXPA02000680A (en) Vgf polypeptides and methods of treating vgf-related disorders.
HK1042523A1 (en) Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
AU5160599A (en) Method for the production of n,n'-carbonyl diazoles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

122 Ep: pct application non-entry in european phase